Cocrystal Pharma, Inc.
COCP
$1.02
$0.010.99%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 0.81% | -20.52% | -70.57% | -73.96% | -53.90% |
| Gross Profit | 15.74% | 20.52% | 70.57% | 73.96% | 53.90% |
| SG&A Expenses | 23.34% | -27.75% | -36.94% | -13.51% | -18.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.25% | -23.19% | -58.57% | -61.31% | -43.70% |
| Operating Income | -0.64% | 23.19% | 58.57% | 61.31% | 43.70% |
| Income Before Tax | 0.09% | 25.72% | 58.51% | 61.54% | 41.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.09% | 25.72% | 58.51% | 61.54% | 41.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.09% | 25.72% | 58.51% | 61.54% | 41.84% |
| EBIT | -0.64% | 23.19% | 58.57% | 61.31% | 43.70% |
| EBITDA | -1.21% | 22.92% | 58.58% | 61.46% | 43.83% |
| EPS Basic | 26.26% | 45.30% | 61.61% | 61.54% | 41.82% |
| Normalized Basic EPS | 26.31% | 45.26% | 61.60% | 61.55% | 41.81% |
| EPS Diluted | 26.26% | 45.30% | 61.61% | 61.54% | 41.82% |
| Normalized Diluted EPS | 26.31% | 45.26% | 61.60% | 61.55% | 41.81% |
| Average Basic Shares Outstanding | 35.50% | 35.77% | 8.03% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 35.50% | 35.77% | 8.03% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |